Navigation Links
ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx

WINDSOR, Ontario, Sept. 19 /PRNewswire/ -- ArtJen Complexus Holdings Corp. ( today announced that, following the results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is being studied by a major US west-coast university medical center. The largest study to date on the patented all- natural soluble fiber that binds dietary fat will involve overweight but not obese individuals.

"Our earlier study with obese, type 2 diabetics demonstrated significant weight loss when adjusted for changes in diet." said FBCx co-inventor, Dr. Catherine Jen. "It's time to look at the non-obese population segment that would benefit from losing 10-25 pounds."

"We expect this study will show FBCx to be an easy and effective aid for losing weight and for lowering elevated levels of blood fats," continued FBCx co-inventor, Dr. Joseph Artiss.

Previous FBCx study findings include:

-- Effective at reducing and/or maintaining body weight in patients with

type 2 diabetes.

-- Lowered both triglyceride and LDL (bad) cholesterol levels in patients

who began the study with elevated triglyceride levels.

-- Blood work findings indicate an insulin sensitivity increase and

therefore a possible delay in the need to institute or the intensity of

insulin therapy in type 2 diabetics.

-- FBCx was shown to bind and remove 9 times its own weight in dietary

fat, essentially preventing 80 calories from being absorbed per tablet.

-- FBCx appears to preferentially bind saturated over unsaturated dietary


-- FBCx produced no adverse side effects.

These findings and others have lead to FBCx being referred to as the "miracle weight loss" pill in media reports and by renowned members of the medical profession.

"We are so convinced of the efficacy of FBCx that we sought out and funded this major study ourselves," said Dr. Artiss.

"I have spent my entire career studying obesity. FBCx works where most others have failed to live up to their hype," stated Dr. Jen.

FBCx co-inventors are Associate Professor of Pathology Joseph Artiss, Ph.D., FACB and K-L Catherine Jen, Ph.D., Professor and Chair of Nutrition and Food Science, both of Wayne State University in Detroit, Michigan.

Six tablets daily are capable of removing 50-60% of the calories from a typical North American diet.

SOURCE ArtJen Complexus Holdings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):